Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(6):462-463; doi:10.1093/jnci/dji077
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Cappuzzo, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Cappuzzo, F.
Related Collections
Right arrowRelated Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

CORRESPONDENCE

RESPONSE: Re: Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non–Small-Cell Lung Cancer

Federico Cappuzzo

Correspondence to: Federico Cappuzzo, MD, Division of Medical Oncology, Bellaria Hospital, Bologna, Italy (e-mail: federico.cappuzzo@ausl.bo.it).

The first 10% of the full text of this article appears below.

Gefitinib is a tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR). Although approximately 10% of non–small-cell lung cancer (NSCLC) patients who received gefitinib had a dramatic response and increased long-term survival, patients not selected for any biologic characteristic who received the drug as a first-line therapy in combination with standard chemotherapy . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Correspondence

Re: Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non–Small-Cell Lung Cancer
Filippo de Braud, Tommaso De Pas, Lorenzo Spaggiari, Giulia Veronesi, Giuseppe Curigliano, Cristina Noberasco, and Giuseppe Pelosi
J Natl Cancer Inst 2005 97: 461-462. [Extract] [Full Text] [PDF]